Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
18 10 2022
18 10 2022
Historique:
received:
12
12
2021
accepted:
27
05
2022
pubmed:
3
8
2022
medline:
20
10
2022
entrez:
2
8
2022
Statut:
ppublish
Résumé
Remission of relapses is an important contributor to both short- and long-term prognosis in relapsing multiple sclerosis (RMS). In MS-associated acute optic neuritis (MS-ON), retinal layer thinning measured by optical coherence tomography (OCT) is a reliable biomarker of both functional recovery and the degree of neuroaxonal damage. However, prediction of non-ON relapse remission is challenging. We aimed to investigate whether retinal thinning after ON is associated with relapse remission after subsequent non-ON relapses. For this longitudinal observational study from the Vienna MS database, we included patients with MS with (1) an episode of acute ON, (2) available spectral domain OCT scans within 12 months before ON onset (OCT We analyzed 167 patients with MS (mean age 36.5 years [SD 12.3], 71.3% women, mean disease duration 3.1 years [SD 4.5]) during a mean observation period of 3.4 years (SD 2.8) after the ON episode. In 61 patients (36.5%), at least 1 relapse showed incomplete remission. In the multivariable analyses, incomplete remission of non-ON relapse was associated with ΔGCIPL thinning both from OCT
Sections du résumé
BACKGROUND AND OBJECTIVES
Remission of relapses is an important contributor to both short- and long-term prognosis in relapsing multiple sclerosis (RMS). In MS-associated acute optic neuritis (MS-ON), retinal layer thinning measured by optical coherence tomography (OCT) is a reliable biomarker of both functional recovery and the degree of neuroaxonal damage. However, prediction of non-ON relapse remission is challenging. We aimed to investigate whether retinal thinning after ON is associated with relapse remission after subsequent non-ON relapses.
METHODS
For this longitudinal observational study from the Vienna MS database, we included patients with MS with (1) an episode of acute ON, (2) available spectral domain OCT scans within 12 months before ON onset (OCT
RESULTS
We analyzed 167 patients with MS (mean age 36.5 years [SD 12.3], 71.3% women, mean disease duration 3.1 years [SD 4.5]) during a mean observation period of 3.4 years (SD 2.8) after the ON episode. In 61 patients (36.5%), at least 1 relapse showed incomplete remission. In the multivariable analyses, incomplete remission of non-ON relapse was associated with ΔGCIPL thinning both from OCT
Identifiants
pubmed: 35918172
pii: WNL.0000000000200970
doi: 10.1212/WNL.0000000000200970
pmc: PMC9620804
doi:
Substances chimiques
Steroids
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1803-e1812Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurology. 2021 Apr 20;96(16):e2058-e2069
pubmed: 33653904
Ann Neurol. 2019 May;85(5):618-629
pubmed: 30851125
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Mult Scler J Exp Transl Clin. 2021 May 28;7(2):20552173211015503
pubmed: 34104471
Clin Neurol Neurosurg. 2006 Mar;108(3):245-9
pubmed: 16384636
Neurology. 2009 Feb 17;72(7):602-8
pubmed: 19221292
Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648
pubmed: 34422112
Arch Ophthalmol. 2008 Jul;126(7):994-5
pubmed: 18625951
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
Mult Scler. 2019 Nov;25(13):1754-1763
pubmed: 30303037
Arch Ophthalmol. 1985 Dec;103(12):1796-806
pubmed: 2866759
Handb Clin Neurol. 2014;122:371-91
pubmed: 24507526
Neurology. 2014 Jun 17;82(24):2173-9
pubmed: 24850491
Brain. 2005 Jan;128(Pt 1):5-6
pubmed: 15596795
Neurology. 2006 Sep 12;67(5):809-13
pubmed: 16966542
Mult Scler. 2015 Feb;21(2):163-70
pubmed: 24948688
Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1841-8
pubmed: 23589277
Neurology. 2015 Aug 25;85(8):722-9
pubmed: 26208962
N Engl J Med. 1998 Jan 29;338(5):278-85
pubmed: 9445407
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
PLoS One. 2016 Jul 08;11(7):e0158978
pubmed: 27391947
Mult Scler. 2012 Aug;18(8):1152-8
pubmed: 22217582
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Mult Scler. 2019 Feb;25(2):196-203
pubmed: 29095097
Scand J Immunol. 2005 Aug;62(2):176-82
pubmed: 16101825
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1264-8
pubmed: 15790888
Neurol Neuroimmunol Neuroinflamm. 2019 Dec 17;7(2):
pubmed: 31848231
Lancet Neurol. 2016 May;15(6):574-84
pubmed: 27011339
Eur J Neurol. 2018 Sep;25(9):1107-e101
pubmed: 29687559
Lancet. 2002 Apr 6;359(9313):1221-31
pubmed: 11955556
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
Mult Scler. 2021 Apr;27(5):684-694
pubmed: 32613912
J Neuroimaging. 2006 Apr;16(2):104-14
pubmed: 16629730
Brain. 2003 Apr;126(Pt 4):770-82
pubmed: 12615637
Mult Scler Relat Disord. 2020 Oct;45:102403
pubmed: 32738702
Ann Neurol. 2015 Mar;77(3):517-28
pubmed: 25559267
Semin Neurol. 2019 Dec;39(6):711-717
pubmed: 31847042
Brain. 1993 Feb;116 ( Pt 1):117-34
pubmed: 8453453